Top Markets
#1 CyberDEX CyberDEX +391.94%
#2 OVERTAKE OVERTAKE +60.20%
#3 deBridge deBridge +25.79%
#4 Clearpool Clearpool +25.70%
#5 Playnance Playnance +23.95%
#6 Nillion Nillion +21.37%
#7 B3 (Base) B3 (Base) +19.47%
#8 AUKI AUKI +15.74%
#9 龙虾 (Lobster) 龙虾 (Lobster) +15.62%
#10 Codatta Codatta +15.06%
Coin of the day
CyberDEX CyberDEX
Settings
Language
ENGLISH
Currency
USD
Theme
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rank in Stocks #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Share Price
$0.00185055
Market Cap
$48.29K
Change (1 day)
-3.55%
Change (1 year)
30.31%
Country
GB
Trade Nuformix plc (NFX)

Category

Healthcare
Number of shares outstanding for Nuformix plc (NFX)
Number of shares outstanding as of March 2026: 2.12B
According to Nuformix plc latest financial reports and stock price the company's current number of shares outstanding is 2.12B. At the end of September 2024 the company had 787.01M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Nuformix plc (NFX) from 2014 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 2.12B 27.71%
2025 1.66B 111.05%
2024 787.01M 9.39%
2023 719.46M 20.22%
2022 598.45M 3.07%
2021 580.63M 21.71%
2020 477.06M 3.54%
2019 460.75M 23.34%
2018 373.55M 290.13%
2017 95.75M 59.34%
2016 60.09M 0.00%
2014 0.00 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -88.03%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -81.33%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -77.42%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -97.07%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH